Drugs / PERTECHNETATE
PERTECHNETATE
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 3 | NCT02980679 | Mar 2017 → Feb 2019 | thyroid gland disorder | University of Alberta | Completed | No outcome recorded |
Evidence & citations 6 cited values
Every value below carries the sentence it was read from. 2 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | PERTECHNETATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109884 ↗ |
| Known as | Cpert | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109884 ↗ |
| Known as | G-PERT | ClinicalTrials.gov intervention name — accepted as the source's own label NCT02980679 ↗ |
| Known as | Technetium (99mtc) pertechnetate | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109884 ↗ |
| Known as | TECHNETIUM TC-99M PERTECHNETATE | ChEMBL registry synonym — accepted as the source's own label CHEMBL2109884 ↗ |
| Modality | Diagnostic / imaging agent | “A 99mTc Pertechnetate (G-PERT) scan is a nuclear medicine test that can create an image of the thyroid gland and other organs.” NCT02980679 ↗ |